

551,103

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau(43) International Publication Date
7 October 2004 (07.10.2004)

PCT

(10) International Publication Number
WO 2004/085658 A1(51) International Patent Classification⁷: **C12N 15/86**,
C07K 14/145, C12N 7/04, A61K 39/205(21) International Application Number:
PCT/CA2004/000460

(22) International Filing Date: 29 March 2004 (29.03.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/457,591 27 March 2003 (27.03.2003) US(71) Applicants (for all designated States except US): **OT-
TAWA HEALTH RESEARCH INSTITUTE** [CA/CA];
725 Parkdale Avenue, Ottawa, Ontario K1Y 4E9 (CA).
WELLSTAT BIOLOGICS CORPORATION [US/US];
930 Clopper Road, Gaithersburg, MD 20878 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BELL, John, C.**
[CA/CA]; 248 Knox Crescent, Ottawa, Ontario K1G 0K8
(CA). **LICHTY, Brian, D.** [CA/CA]; 471 Castor Rd,
RR#2, Russell, Ontario K4R 1E5 (CA). **STOJDL, David,**
F. [CA/CA]; 17 Great Oak Private, Ottawa, Ontario K1G
6P7 (CA).(74) Agents: **WHITE, Stephanie, R.** et al.; Osler, Hoskin &
Harcourt LLP, Suite 1500, 50 O'Connor Street, Ottawa, On-
tario K1P 6L2 (CA).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), Euro-
pean (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,
GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).**Published:**

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.(54) Title: **MUTANT VESICULAR STOMATITIS VIRUSES AND USE THEREOF**(57) Abstract: The present invention provides mutant viruses with a decreased ability to block nuclear transport of mRNA or protein in an infected cell which are attenuated *in vivo*. The mutant viruses of the present invention may also be capable of triggering the anti-viral systems of normal host cells while remaining sensitive to the effects of these systems. The present invention further provides for the use of the mutant viruses in a range of applications including, but not limited to, as therapeutics for the treatment of cancer and infections, as vaccines and adjuvants, as viral vectors, and as oncolytic and cytolytic agents for the selective lysis of malignant or infected cells.

WO 2004/085658 A1